They say that the market never bottoms on a Friday and I wonder if the same is true of topping? The sector has clearly had a strong near term move and is due for a pause but would strength today be the near term top or is there more to go? Over the longer term […]
July 24 Biotech Update
It should be a big week for news but it is starting a little slow, which is not unexpected as the earnings are clustered Tuesday through Thursday. There is some minor news to start the week but it is simply a small appetizer as to what should be a week of news. That being said […]
July 21 Biotech Update
I am back and missed all the fireworks yesterday. This week has gone quite well for the sector in terms of fundamentals and the price action reflected it. We sort of dodge a bullet as continued weakness would have been a significant problem. News will continue next week with the start of the large cap […]
July 18 Biotech Update
There seems to be a negative pattern developing with strength early that gives way to weakness later in the day. This is not totally unexpected given the need to consolidate but it is certainly sending a signal. We have a set of good news last night and this morning and this should be the strongest […]
July 17 Biotech Update
A little bit of news to start the week but nothing dramatic and still none of the M&A that was supposed to explode this year leading the recovery of the sector. It is starting to look like the next big set of catalysts for the sector will be earnings that are actually starting this week […]
May 26 Biotech Update
There is no news to speak of so I want to end the week with some broader sector commentary. There are some broader undercurrents that seem to be continuing and it seems to be producing an odd effect on the sector. 1. The first point on the sector is that this is about as frustrated […]
May 4 Biotech Update
It looks like a vote is set for TrumpCare in the House and while it will be close I lean towards it passing. Congress is heading towards a recess so I suspect many republicans are going to vote to give Trump a win. It is a low cost vote as it will not pass the […]
April 28 Biotech Update
A lot has happened in terms of news in the sector, although there is nothing that was thesis changing. There are some new potential trends to watch but at this point I think most of the news was more or less incremental. I will flesh out more of the ideas in the coming days but […]
April 25 Biotech Update
The market continues to have a tail wind as France and North Korean risks are being removed (although not sure we are quite out of the woods on North Korea but could be relatively soon). The sector seems to be participating a little more today, which is a positive sign but as I noted yesterday […]
April 24 Biotech Update
The market is surging and is dragging the sector higher with it. It seems to me that the sector is not doing particularly well given the new risk on environment but it is also not doing exceptionally poor. We had a large M&A announcement but it was med tech so we are still waiting for […]
Dave Trading – April 2017
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
March 8 Biotech Update
I was not too busy to write yesterday but there was really nothing that I could find that was interesting enough to write about. I looked for something and there was a big lack of company specific news and that is the case today as well. We are a little too early to talk about […]
March 3 Biotech Update
I think the sector has been rational the past couple of days in that good news is generally moving stocks higher and bad news lower. If there was a broader trend I would say weak but it almost seems out of sync with the broader market. When the broader market rallied the sector lagged and […]
March 1 Biotech Update
Not a lot of news the past couple of days but certainly some interesting events to talk about. I will focus on two but more generally the sector is doing well. There seems to be some more interest in the sector and the move in CELG might be that early warning signal of generalist interest […]
February 27 Biotech Update
I have snuck into work during this Mardi Gras break but not much to write on so this will be a quick update and will likely be back later in the week. 1. ONCS held up better than I thought it would and with the fast track news today and KOL talk tomorrow, I will […]
February 21 Biotech Update
Long weekend and a significant lack of news. I do not think there was an expectation of big news but sometimes these long weekends can surprise with a flurry of mergers- not today. Without anything major I will do a series of quick hits on the news since last Friday. Market is doing well to […]
February 3 Biotech Update
I was correct in my prediction that I would need to take care of a sick child (and still need to do so today but have some more time). It has been an interesting week but pretty much expected. I will circle around to what I saw as the most interesting and important events. 1. […]
Dave Trading – February 2017
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
January 23 Biotech Update
There is not a lot of new news out this week but this is a week where earnings start, which could pick up the pace a little in terms of fundamental news. Two potential caveats. First, coming on the heels of JPM there is likely not a lot of new information to be provided. Companies […]
Dave Trading – January 2017
*** David Sobek is a disciplined value investor. Using models, research, and fundamental data, David devises a value for biotech stocks, buys when significantly undervalued, and sells when significantly overvalued.*** As a reminder, this is my personal guide. You can alter it in accordance with your risk tolerance. >3 Standard deviations – No position 2-3 […]
